5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain

Efrain Azmitia, Valeria J. Rubinstein, James A. Strafaci, Jose C. Rios, Patricia M. Whitaker-Azmitia

Research output: Contribution to journalArticle

Abstract

Serotonin and dexamethasone act as differentiating agents during development. Reducing circulating adrenal steroids or central 5-HT levels via adrenalectomy (ADX) or the tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA), respectively, has been shown to have de-differentiating effects in the adult brain. Morphometric analysis of 5-HT, S100β, MAP-2 and synaptophysin immunoreactivity (IR) was used to follow the molecular plasticity of several brain regions after lesioning of 5-HT nerve terminals by para-chloroamphetamine (PCA; 2 × 10 mg/kg s.c.), a serotonin neurotoxin. Two weeks after PCA treatment we observed reductions of 5-HT, S100β, and MAP-2 IR in parietal and temporal cortex, temporal pole, hippocampus and hypothalamus. The reductions in MAP-2 and synaptophysin-IR were reversed by 3 days of treatment with dexamethasone (10 mg/l drinking water) or ipsapirone, a 5-HT1A agonist (1 mg/kg s.c.). The loss of S100-IR was reversed only by the 5-HT1A agonist. These results indicate that both dexamethasone and serotonin have effects on adult neuronal plasticity but may work via different mechanisms. The implications of these findings to the loss of synaptophysin and MAP-2 staining in Alzheimer's disease are discussed.

Original languageEnglish (US)
Pages (from-to)181-192
Number of pages12
JournalBrain Research
Volume677
Issue number2
DOIs
StatePublished - Apr 24 1995

Fingerprint

p-Chloroamphetamine
Serotonin 5-HT1 Receptor Agonists
Synaptophysin
Dexamethasone
Serotonin
Brain
Fenclonine
Serotonin Agents
Tryptophan Hydroxylase
Parietal Lobe
Passive Cutaneous Anaphylaxis
Neuronal Plasticity
Adrenalectomy
Neurotoxins
Temporal Lobe
Drinking Water
Hypothalamus
Hippocampus
Alzheimer Disease
Steroids

Keywords

  • Hippocampus
  • Hypothalamus
  • Immunocytochemistry
  • Morphometry
  • Parietal cortex
  • S100β, synaptophysin
  • Serotonin
  • Temporal cortex
  • Temporal pole

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. / Azmitia, Efrain; Rubinstein, Valeria J.; Strafaci, James A.; Rios, Jose C.; Whitaker-Azmitia, Patricia M.

In: Brain Research, Vol. 677, No. 2, 24.04.1995, p. 181-192.

Research output: Contribution to journalArticle

Azmitia, Efrain ; Rubinstein, Valeria J. ; Strafaci, James A. ; Rios, Jose C. ; Whitaker-Azmitia, Patricia M. / 5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. In: Brain Research. 1995 ; Vol. 677, No. 2. pp. 181-192.
@article{f41d321403e94754bbd1062a96b77829,
title = "5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain",
abstract = "Serotonin and dexamethasone act as differentiating agents during development. Reducing circulating adrenal steroids or central 5-HT levels via adrenalectomy (ADX) or the tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA), respectively, has been shown to have de-differentiating effects in the adult brain. Morphometric analysis of 5-HT, S100β, MAP-2 and synaptophysin immunoreactivity (IR) was used to follow the molecular plasticity of several brain regions after lesioning of 5-HT nerve terminals by para-chloroamphetamine (PCA; 2 × 10 mg/kg s.c.), a serotonin neurotoxin. Two weeks after PCA treatment we observed reductions of 5-HT, S100β, and MAP-2 IR in parietal and temporal cortex, temporal pole, hippocampus and hypothalamus. The reductions in MAP-2 and synaptophysin-IR were reversed by 3 days of treatment with dexamethasone (10 mg/l drinking water) or ipsapirone, a 5-HT1A agonist (1 mg/kg s.c.). The loss of S100-IR was reversed only by the 5-HT1A agonist. These results indicate that both dexamethasone and serotonin have effects on adult neuronal plasticity but may work via different mechanisms. The implications of these findings to the loss of synaptophysin and MAP-2 staining in Alzheimer's disease are discussed.",
keywords = "Hippocampus, Hypothalamus, Immunocytochemistry, Morphometry, Parietal cortex, S100β, synaptophysin, Serotonin, Temporal cortex, Temporal pole",
author = "Efrain Azmitia and Rubinstein, {Valeria J.} and Strafaci, {James A.} and Rios, {Jose C.} and Whitaker-Azmitia, {Patricia M.}",
year = "1995",
month = "4",
day = "24",
doi = "10.1016/0006-8993(95)00051-Q",
language = "English (US)",
volume = "677",
pages = "181--192",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - 5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain

AU - Azmitia, Efrain

AU - Rubinstein, Valeria J.

AU - Strafaci, James A.

AU - Rios, Jose C.

AU - Whitaker-Azmitia, Patricia M.

PY - 1995/4/24

Y1 - 1995/4/24

N2 - Serotonin and dexamethasone act as differentiating agents during development. Reducing circulating adrenal steroids or central 5-HT levels via adrenalectomy (ADX) or the tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA), respectively, has been shown to have de-differentiating effects in the adult brain. Morphometric analysis of 5-HT, S100β, MAP-2 and synaptophysin immunoreactivity (IR) was used to follow the molecular plasticity of several brain regions after lesioning of 5-HT nerve terminals by para-chloroamphetamine (PCA; 2 × 10 mg/kg s.c.), a serotonin neurotoxin. Two weeks after PCA treatment we observed reductions of 5-HT, S100β, and MAP-2 IR in parietal and temporal cortex, temporal pole, hippocampus and hypothalamus. The reductions in MAP-2 and synaptophysin-IR were reversed by 3 days of treatment with dexamethasone (10 mg/l drinking water) or ipsapirone, a 5-HT1A agonist (1 mg/kg s.c.). The loss of S100-IR was reversed only by the 5-HT1A agonist. These results indicate that both dexamethasone and serotonin have effects on adult neuronal plasticity but may work via different mechanisms. The implications of these findings to the loss of synaptophysin and MAP-2 staining in Alzheimer's disease are discussed.

AB - Serotonin and dexamethasone act as differentiating agents during development. Reducing circulating adrenal steroids or central 5-HT levels via adrenalectomy (ADX) or the tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA), respectively, has been shown to have de-differentiating effects in the adult brain. Morphometric analysis of 5-HT, S100β, MAP-2 and synaptophysin immunoreactivity (IR) was used to follow the molecular plasticity of several brain regions after lesioning of 5-HT nerve terminals by para-chloroamphetamine (PCA; 2 × 10 mg/kg s.c.), a serotonin neurotoxin. Two weeks after PCA treatment we observed reductions of 5-HT, S100β, and MAP-2 IR in parietal and temporal cortex, temporal pole, hippocampus and hypothalamus. The reductions in MAP-2 and synaptophysin-IR were reversed by 3 days of treatment with dexamethasone (10 mg/l drinking water) or ipsapirone, a 5-HT1A agonist (1 mg/kg s.c.). The loss of S100-IR was reversed only by the 5-HT1A agonist. These results indicate that both dexamethasone and serotonin have effects on adult neuronal plasticity but may work via different mechanisms. The implications of these findings to the loss of synaptophysin and MAP-2 staining in Alzheimer's disease are discussed.

KW - Hippocampus

KW - Hypothalamus

KW - Immunocytochemistry

KW - Morphometry

KW - Parietal cortex

KW - S100β, synaptophysin

KW - Serotonin

KW - Temporal cortex

KW - Temporal pole

UR - http://www.scopus.com/inward/record.url?scp=0028986568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028986568&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(95)00051-Q

DO - 10.1016/0006-8993(95)00051-Q

M3 - Article

VL - 677

SP - 181

EP - 192

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -